bs-6678C
[Life Science]
Mavoglurant
DATASHEET
Formulation Powder
Storage: Store in dry, dark place at -20C for 1 year.
Product Information:
Molecular Weight: 313.39
Formula: C19 H23 N O3
CAS Number: 543906-09-8
InChi Key: ZFPZEYHRWGMJCV-ZHALLVOQSA-N
InChi: InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
Smiles: CC1C=CC=C(C=1)C#C[C@]1(O)CCC[C@@H]2[C@H]1CCN2C(=O)OC
Purity: 98.0
Solubility: Soluble in DMSO, not in water
Appearance: Solid Power.
Shelf Life: 1.0 years
Formula: C19 H23 N O3
CAS Number: 543906-09-8
InChi Key: ZFPZEYHRWGMJCV-ZHALLVOQSA-N
InChi: InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1
Smiles: CC1C=CC=C(C=1)C#C[C@]1(O)CCC[C@@H]2[C@H]1CCN2C(=O)OC
Purity: 98.0
Solubility: Soluble in DMSO, not in water
Appearance: Solid Power.
Shelf Life: 1.0 years
Description:
Mavoglurant, aslo known as AFQ056, is an experimental drug candidate for the treatment of fragile X syndrome. Mavoglurant exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5). Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results. Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder.
Size: 10mg solid, 2mg solid 10mg solid, 2mg solid
Applications: Life Science()
For research use only. Not intended for diagnostic or therapeutic use.